Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
基本信息
- 批准号:9073896
- 负责人:
- 金额:$ 34.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-17 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAdverse eventAffectAfricaAgeAge-MonthsAnemiaAnti-Retroviral AgentsBirthBotswanaBreast FeedingCharacteristicsChildCotrimoxazoleCounselingDataDeveloping CountriesDistrict HospitalsDouble-Blind MethodEnrollmentEquilibriumEventExclusive BreastfeedingFeeding MethodsGoalsGovernmentGrowthHIVHIV InfectionsHIV-1HIV-exposed uninfected infantHematologyHighly Active Antiretroviral TherapyHospitalizationIndividualInfantInfant MortalityInfant formulaInterventionIntervention StudiesLifeMeasuresMorbidity - disease rateMothersNeutropeniaNevirapineOutcomePerinatalPlacebosPregnant WomenPreventionProphylactic treatmentQualifyingRandomizedResearch DesignResistanceRiskSafetySpecimenSurvival RateTimeToxic effectWeaningWomanWorld Health Organizationabstractingadverse outcomearmbaseclinically significantcohortdouble-blind placebo controlled trialearly childhoodfeedinghigh riskimprovedinfancymeetingsmortalitynovelpathogenpostnatalpregnantpreventprophylacticrandomized placebo controlled trialrandomized trialrespiratorystandard of caretransmission processtrial comparing
项目摘要
DESCRIPTION (provided by applicant): Abstract Priorities for improving infant HIV-free survival in the developing world include preventing late mother-to-child HIV transmission (MTCT) during breastfeeding (BF) and reducing infant mortality after weaning. We hypothesize that cotrimoxazole (CTX) prophylaxis may reduce mortality among HIV-exposed but uninfected infants, particularly early in life for formula fed (FF) infants and after weaning in BF infants. CTX may therefore allow feeding strategies that reduce the period of BF and minimize MTCT risk. The proposed study is a randomized, double-blinded, placebo-controlled trial among 3,308 mother/infant pairs. The trial will compare survival (and HIV-free survival) at 12 months among infants receiving CTX vs. placebo from 4 weeks through 12 months. Feeding strategy will be observational, and the CTX vs. placebo randomization will be balanced across feeding methods. Supported feeding options will include exclusive BF + infant nevirapine prophylaxis for up to 3 months, exclusive BF + maternal HAART (if available) for up to 6 months, or FF from birth. The primary endpoint will be survival at 12 months by CTX or placebo arm. Secondary endpoints will evaluate survival and morbidity/mortality at 18 months; safety of CTX prophylaxis; survival (and HIV-free survival) between CTX/placebo arms by feeding method; MTCT by chosen feeding method at 1, 3, 6, and 12 months; survival with early vs. later weaning; and an analysis of maternal characteristics as predictors for feeding choice and HIV-free survival. All mothers and infants will receive antenatal and peripartum standard of care prophylaxis from the Botswana Government to prevent MTCT. HAART and CTX will be available from the Botswana Government for all qualifying HIV-infected women and infants.
描述(申请人提供):摘要提高发展中国家婴儿无艾滋病毒存活率的优先事项包括预防母乳喂养(BF)期间的晚期母婴艾滋病毒传播(MTCT)和降低婴儿断奶后的死亡率。我们假设,复方新诺明(CTX)预防可以降低HIV感染但未感染的婴儿的死亡率,特别是在配方奶(FF)婴儿的生命早期和BF婴儿断奶后。因此,CTX可能允许采取喂养策略,以缩短BF的时间并将母婴传播的风险降至最低。这项拟议的研究是一项随机、双盲、安慰剂对照试验,涉及3308对母婴。这项试验将比较接受CTX治疗的婴儿和服用安慰剂的婴儿在4周到12个月期间的12个月存活率(和无艾滋病毒存活率)。喂养策略将是观察性的,CTX与安慰剂的随机对照将在喂养方法上进行平衡。支持的喂养选项将包括最多3个月的独家BF+婴儿奈韦拉平预防,最多6个月的独家BF+产妇HAART(如果有),或从出生起的FF。主要终点将是服用CTX或安慰剂的患者在12个月内存活。次级终点将评估18个月后的生存率和发病率/死亡率;环磷酰胺预防的安全性;通过喂养方法的环磷酰胺/安慰剂组之间的存活(和无艾滋病毒生存);在1、3、6和12个月时按选择的喂养方法进行的母婴传播;早期断奶与较晚断奶的生存;以及作为喂养选择和无艾滋病毒生存预测因素的母亲特征分析。所有母亲和婴儿都将接受博茨瓦纳政府提供的产前和围产期预防标准护理,以预防母婴传播。博茨瓦纳政府将为所有符合条件的艾滋病毒感染妇女和婴儿提供HAART和CTX。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHAHIN LOCKMAN其他文献
SHAHIN LOCKMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHAHIN LOCKMAN', 18)}}的其他基金
Addressing Major HIV Prevention and Health Outcomes Questions in an Era of Universal ART: Mentoring in a Community-Randomized Trial
解决普遍抗逆转录病毒治疗时代的主要艾滋病毒预防和健康结果问题:社区随机试验中的指导
- 批准号:
10112810 - 财政年份:2017
- 资助金额:
$ 34.81万 - 项目类别:
Mentoring in Global Patient-Oriented HIV Research in the Era of COVID-19 and Universal ART
COVID-19 和通用 ART 时代全球以患者为导向的艾滋病毒研究的指导
- 批准号:
10483694 - 财政年份:2017
- 资助金额:
$ 34.81万 - 项目类别:
Mentoring in Global Patient-Oriented HIV Research in the Era of COVID-19 and Universal ART
COVID-19 和通用 ART 时代全球以患者为导向的艾滋病毒研究的指导
- 批准号:
10669765 - 财政年份:2017
- 资助金额:
$ 34.81万 - 项目类别:
Training in HIV Genomics, Treatment, and Cure Research in Botswana
博茨瓦纳的艾滋病毒基因组学、治疗和治愈研究培训
- 批准号:
10688707 - 财政年份:2013
- 资助金额:
$ 34.81万 - 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
- 批准号:
9975952 - 财政年份:2013
- 资助金额:
$ 34.81万 - 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
- 批准号:
10396618 - 财政年份:2013
- 资助金额:
$ 34.81万 - 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
- 批准号:
10161878 - 财政年份:2013
- 资助金额:
$ 34.81万 - 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
- 批准号:
10462051 - 财政年份:2013
- 资助金额:
$ 34.81万 - 项目类别:
Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
- 批准号:
8316378 - 财政年份:2010
- 资助金额:
$ 34.81万 - 项目类别:
Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
- 批准号:
8144267 - 财政年份:2010
- 资助金额:
$ 34.81万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 34.81万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 34.81万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 34.81万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 34.81万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 34.81万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 34.81万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 34.81万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 34.81万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 34.81万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 34.81万 - 项目类别: